Association of CD31 and p53 With Survival of Ovarian Cancer Patients.
Biomarkers, Tumor
/ metabolism
Carcinoma, Ovarian Epithelial
/ metabolism
Cell Differentiation
Denmark
Disease Progression
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Neoplasm Staging
Ovarian Neoplasms
/ metabolism
Platelet Endothelial Cell Adhesion Molecule-1
/ metabolism
Prognosis
Risk Factors
Tumor Suppressor Protein p53
/ metabolism
CD31
ovarian cancer
p53
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
05
12
2018
revised:
14
12
2018
accepted:
17
12
2018
entrez:
4
2
2019
pubmed:
4
2
2019
medline:
21
3
2019
Statut:
ppublish
Résumé
New markers for ovarian cancer are needed. This study aimed to examine the expression of tumour cell p53 and endothelial cell CD31 proteins and correlate them to clinicopathological factors. Expression of proteins was immunohistochemically assessed using tissue sections from 585-599 ovarian cancer patients from the Danish MALOVA study. High CD31 expression was found in poorly differentiated tumours (p=0.0006), and high p53 expression was found in poorly differentiated cancers (p<0.0001), high clinical stage (p<0.0001), non-radical surgery (p<0.0001) and high serum CA-125 values (p<0.0001). CD31 expression showed no prognostic survival value, but high hazard ratios were found for patients with high p53 expression (HR=2.313, p<0.0001). An interaction was found between p53 and stage of cancer, suggesting a prognostic impact of p53 in low-stage, but not in advanced-stage cancer. More than 5% of p53 tissue expression may predict shorter survival of ovarian cancer patients and may be useful for predicting the risk of disease progression in low-stage patients following primary surgery. CD31 has no strong prognostic value.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
New markers for ovarian cancer are needed. This study aimed to examine the expression of tumour cell p53 and endothelial cell CD31 proteins and correlate them to clinicopathological factors.
PATIENTS AND METHODS
METHODS
Expression of proteins was immunohistochemically assessed using tissue sections from 585-599 ovarian cancer patients from the Danish MALOVA study.
RESULTS
RESULTS
High CD31 expression was found in poorly differentiated tumours (p=0.0006), and high p53 expression was found in poorly differentiated cancers (p<0.0001), high clinical stage (p<0.0001), non-radical surgery (p<0.0001) and high serum CA-125 values (p<0.0001). CD31 expression showed no prognostic survival value, but high hazard ratios were found for patients with high p53 expression (HR=2.313, p<0.0001). An interaction was found between p53 and stage of cancer, suggesting a prognostic impact of p53 in low-stage, but not in advanced-stage cancer.
CONCLUSION
CONCLUSIONS
More than 5% of p53 tissue expression may predict shorter survival of ovarian cancer patients and may be useful for predicting the risk of disease progression in low-stage patients following primary surgery. CD31 has no strong prognostic value.
Identifiants
pubmed: 30711931
pii: 39/2/567
doi: 10.21873/anticanres.13149
doi:
Substances chimiques
Biomarkers, Tumor
0
Platelet Endothelial Cell Adhesion Molecule-1
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
567-576Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.